# MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

> **NCT05776017** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Vac4All** · enrollment: 465 (estimated)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** MSP3-CRM-Vac4All/ Alhydrogel®
- **BIOLOGICAL:** Anti-Rabies Vaccine

## Key facts

- **NCT ID:** NCT05776017
- **Lead sponsor:** Vac4All
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-27
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 465 (ESTIMATED)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776017, "MSP3-CRM-Vac4All/ Alhydrogel® Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05776017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*